Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Export

@article{citeulike:4235637, abstract = {BACKGROUND AND PURPOSE: In hypertensive stroke patients, for the same level of blood pressure control, eprosartan will be more effective than nitrendipine in reducing cerebrovascular and cardiovascular morbidity and mortality. METHODS: A total of 1405 well-defined, high-risk hypertensives with cerebral event during the last 24 months (proven by cerebral computed tomography scan or nuclear magnetic resonance) were randomized to eprosartan or nitrendipine (mean follow-up 2.5 years). Primary end point was the composite of total mortality and all cardiovascular and cerebrovascular events, including all recurrent events. RESULTS: Randomization was successful without significant differences in the baseline characteristics. Blood pressure was reduced to a comparable extent without any significant differences between the 2 groups during the whole study period (150.7/84 mm Hg and 152.0/87.2 mm Hg with eprosartan and nitrendipine therapy to 137.5/80.8 mm Hg and 136.0/80.2 mm Hg, respectively, confirmed by ambulatory blood pressure monitoring). Moreover, already after 3 months, normotensive mean values were achieved, and 75.5\% reached values <140/90 mm Hg with the eprosartan regimen and 77.7\% with the nitrendipine regimen. During follow-up, in total, 461 primary events occurred: 206 eprosartan and 255 nitrendipine (incidence density ratio [IDR], 0.79; 95\% CI, 0.66 to 0.96; P=0.014). Cardiovascular events were: 77 eprosartan and 101 nitrendipine (IDR, 0.75; 95\% CI, 0.55 to 1.02; P=0.06); cerebrovascular events: 102 eprosartan and134 nitrendipine (IDR, 0.75; 95\% CI, 0.58 to 0.97; P=0.03). CONCLUSIONS: The Morbidity and Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary Prevention (MOSES) study was the first to compare an angiotensin II type 1 receptor antagonist with a calcium antagonist in secondary stroke prevention. In these high-risk hypertensive stroke patients, an early normotensive and comparable blood pressure was achieved. The combined primary end point was significantly lower in the eprosartan group.}, author = {Schrader, J. and L\"{u}ders, S. and Kulschewski, A. and Hammersen, F. and Plate, K. and Berger, J. and Zidek, W. and Dominiak, P. and Diener, H. C. and {}}, citeulike-article-id = {4235637}, citeulike-linkout-0 = {http://dx.doi.org/10.1161/01.STR.0000166048.35740.a9}, citeulike-linkout-1 = {http://view.ncbi.nlm.nih.gov/pubmed/15879332}, citeulike-linkout-2 = {http://www.hubmed.org/display.cgi?uids=15879332}, comment = {MOSES stroke arb eprosartan v ccb nitrendipine}, doi = {10.1161/01.STR.0000166048.35740.a9}, issn = {1524-4628}, journal = {Stroke; a journal of cerebral circulation}, keywords = {arb, ccb, eprosartan, htn, nitrendipine, stroke}, month = {June}, number = {6}, pages = {1218--1226}, posted-at = {2009-03-30 00:01:16}, priority = {2}, title = {Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).}, url = {http://dx.doi.org/10.1161/01.STR.0000166048.35740.a9}, volume = {36}, year = {2005} }

TY - JOUR ID - citeulike:4235637 L3 - citeulike-article-id:4235637 N2 - BACKGROUND AND PURPOSE: In hypertensive stroke patients, for the same level of blood pressure control, eprosartan will be more effective than nitrendipine in reducing cerebrovascular and cardiovascular morbidity and mortality. METHODS: A total of 1405 well-defined, high-risk hypertensives with cerebral event during the last 24 months (proven by cerebral computed tomography scan or nuclear magnetic resonance) were randomized to eprosartan or nitrendipine (mean follow-up 2.5 years). Primary end point was the composite of total mortality and all cardiovascular and cerebrovascular events, including all recurrent events. RESULTS: Randomization was successful without significant differences in the baseline characteristics. Blood pressure was reduced to a comparable extent without any significant differences between the 2 groups during the whole study period (150.7/84 mm Hg and 152.0/87.2 mm Hg with eprosartan and nitrendipine therapy to 137.5/80.8 mm Hg and 136.0/80.2 mm Hg, respectively, confirmed by ambulatory blood pressure monitoring). Moreover, already after 3 months, normotensive mean values were achieved, and 75.5% reached values <140/90 mm Hg with the eprosartan regimen and 77.7% with the nitrendipine regimen. During follow-up, in total, 461 primary events occurred: 206 eprosartan and 255 nitrendipine (incidence density ratio [IDR], 0.79; 95% CI, 0.66 to 0.96; P=0.014). Cardiovascular events were: 77 eprosartan and 101 nitrendipine (IDR, 0.75; 95% CI, 0.55 to 1.02; P=0.06); cerebrovascular events: 102 eprosartan and134 nitrendipine (IDR, 0.75; 95% CI, 0.58 to 0.97; P=0.03). CONCLUSIONS: The Morbidity and Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary Prevention (MOSES) study was the first to compare an angiotensin II type 1 receptor antagonist with a calcium antagonist in secondary stroke prevention. In these high-risk hypertensive stroke patients, an early normotensive and comparable blood pressure was achieved. The combined primary end point was significantly lower in the eprosartan group. IS - 6 JF - Stroke; a journal of cerebral circulation SN - 1524-4628 EP - 1226 TI - Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). VL - 36 SP - 1218 KW - arb KW - ccb KW - eprosartan KW - htn KW - nitrendipine KW - stroke N1 - MOSES stroke arb eprosartan v ccb nitrendipine AU - Schrader, J AU - Lüders, S AU - Kulschewski, A AU - Hammersen, F AU - Plate, K AU - Berger, J AU - Zidek, W AU - Dominiak, P AU - Diener, HC PY - 2005/06// UR - http://dx.doi.org/10.1161/01.STR.0000166048.35740.a9 ER -